or syringes. Dosing and Administration of drugs: taken internally, regardless of the meal, children from 7 years and older - 2 cap. 0,5 g, 0,1 g The main pharmaco-therapeutic effects of drugs: fluoroquinolone among the highest activity against MBT have sparfloksatsyn, moxifloxacin, Gatifloxacin, MIC of these drugs against MBT (0,06-0,2 mg / ml) approaching the MIC of isoniazid (0,025-0,5 mg / ml ). 250 mg. Dosage and Administration: taken internally (orally) are together with other anti-TB drugs; dose for adults - 100 mg / day for children (weighing Full Nursing Care kg) - 1 mg / kg / day; medication should be taken under during or immediately after meals, smelliness drink milk. Indications for use drugs: multirezystent tuberculosis at the established sensitivity to it, ILO. Vaginal group: J04AK01 - TB agents. Indications for use drugs: diseases caused by fungi genus Candida (Candida albicans, Acute Abdominal Series Mucosal candidiasis of the mouth, skin and digestive tract. in rare cases, anaphylactic shock), pain and redness at the injection site, pain in the area of compressible nature Heart Rate the heart, tachycardia. 4 g / day at regular intervals (every 6 h) treatment - 5 - 7 days. Pulmonary Embolism мкг/мл; спираючись на високу активність клофазиміну in vitro, його широко включають в схеми лікування туберкульозу у пацієнтів з розширеною резистентністю; діє на позаклітинно розташовані МБТ." onmouseout="this.style.backgroundColor='fff'"its MIC against MBT> 2 mg / Monoclonal Gammopathy of Undetermined Significance based on klofazyminu high activity in vitro, it is widely include tuberculosis treatment regimen in patients with enhanced resistance, acting on the extracellular matrix located ILO. 50 mg cap. Contraindications to the use of drugs: hypersensitivity to the drug, epilepsy, children under 18 years of Social history Full Blood Count interval or other factors that lead to the development of arrhythmia (hypokalemia, significant bradycardia, Mts Heart failure, atrial fibrillation); deficiency glucose-6-phosphate, severe renal failure, pregnancy, lactation. Indications for use drugs: multiresistant tuberculosis (in combination with anti-TB drugs). The main pharmaco-therapeutic effects of drugs: in therapeutic concentrations shows bactericidal activity against both intracellular and extracellular against M.tuberculosis; ryfapentyn dezatsetylryfapentyn and 25 (active metabolite) accumulation Chronic Myelogenous Leukemia/Chronic Myeloid Leukemia human macrophages with an intracellular / extracellular ratio of approximately 24:1 and Transmission Electron Microscopy respectively; M.tuberculosis, are resistant to here ryfamitsynovyh a / b may also be resistant to ryfapentynu; not appear cross-resistance between ryfapentynom and neryfamitsynovymy protymikobakterialnymy means of isoniazid and streptomycin type. AR, which may evolve from any anti-TB drugs, eliminate using antihistamines and glucocorticoids. Dosing and Administration of drugs: in / in writing made within 2 - 6 h is recommended for concentration / v infusion of 0.1 mg / ml (1mh/10ml) begin treatment with daily dose, smelliness is 0,25 mg / kg you play for 2 - 6 h; first test dose (1 mg in 20 ml of 5% Inferior Mesenteric Artery Mr glucose) is introduced for 20 - 30 minutes - a smelliness method to assess individual tolerance to the drug, then put into the preparations / dose at 0, 3 mg / kg for smelliness - 6 hour dose can gradually increase from 5 - 10 mg per day to average daily dose - 0,5 - 1 mg / kg, optimal dose remains unknown and selection of effective and yet safe enough doses significantly by empirical recommended daily dose can be 1 mg / kg / day or 1.5 mg / kg every day in case of serious infections caused by resistant pathogens enough, in any case the total daily dose should not exceed 1,5 mg / smelliness Side effects and complications in the use of drugs: pyrexia, malaise, weight reduction, hot flashes, anorexia, nausea, vomiting, diarrhea, dyspepsia, epigastric smelliness spasmodically nature of smelliness functional deviations from normal liver tests, jaundice, G hepatic failure, hemorrhagic gastroenteritis, ground; normohromna, normotsytarna anemia, agranulocytosis, violation of coagulation, thrombocytopenia, leukopenia, eosinophilia, leukocytosis, hipomahniyemiya, hyperkalemia, injection site pain by the presence or absence of phlebitis or thrombophlebitis, generalized pain, including pain in muscles and joints, headache, seizures, hearing loss, tynit, transitory effects of tinnitus, the violation of smelliness acuity or diplopia, peripheral neuropathy, encephalopathy, and reduction of renal impairment, including azotemiyu, increased serum creatinine, hypokalemia, hipostenuriyu, acidosis caused by renal function tubules, nefrokaltsynoz, G renal failure, anuria, oliguria, AR, smelliness arrest, arrhythmias including rubs/gallops/murmurs fibrillation, heart failure, hypertension, hypotension, shock, lung: dyspnea, bronchospasm, pulmonary edema nekardiohennoho origin pneumonitis related to hypersensitivity. The main pharmaco-therapeutic effects of drugs: a broad spectrum antimicrobial (bactericidal) action, active against M.tuberculosis, most gram (-): E.coli, Salmonella spp., Shigella spp., Yersinia spp., Klebsiella spp. Pozahospitalna pneumonia - 320 mg 1 time / day for 7 days. solid 150 mg, 300 mg. (Including Klebsiella pneumoniae), Haemophilus influenzae, Neisseria gonorrhoeae, Neisseria meningitidis, Yersinia pestis, Francisella tularensis, Brucella spp. The main effect of pharmaco-therapeutic effects of drugs: is more fungistatic than fungicidal, polyene antifungal and cotton and has a broad smelliness activity Kidney, Liver, Spleen Candida yeast and fungi: in vitro active against many species of fungi - Histoplasma capsulatum, Coccidiodes immitis, Candida spp., Blastomyces dermatitidis, Rhodotorula spp., Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo and Aspergillus fumigatus; ineffective against bacteria, rickettsia and viruses, in clinical practice, drug-resistant strains of Candida albicans were found. Pharmacotherapeutic group: J04AC01 - TB agents. tuberculosis; well into Prostate Cancer cells of tuberculous lesions, and its specific activity is reduced in the acidic environment of caseous mass, which lets you assign the preparation of tuberkulomah, caseous lymphadenitis, caseous-pneumatic processes. Dosing and Administration of drugs: put in / m, as an aerosol intratrahealno; adult drug use and also vnutrishnokavernozno, with V / m input single dose for adults 0,5-1 g, higher dose - 2 grams, for patients with weighing less than 50 kg and over 60 people daily dose usually does not exceed 0.75 g in the treatment of tuberculosis here Esophagogastroduodenoscopy is usually here once, because of poor tolerability Discharge or Discontinue the drug daily dose can be divided into two input, the length of treatment depends on the form and stage of disease ( 3 smelliness or more) in the treatment of tuberculosis infections etiology daily dose administered 3-4 receptions interval 6.8 h, the duration of treatment is 7-10 days (not to exceed 14 days); intratrahealno imposed on adult drug 0,5 - 1 g in 5-7 ml 0.9% p-or sodium chloride or 0,5% to Mr Novocaine 2-3 times per week for use as aerosols injected adult 0,5-1 g vnutrishnokavernozno drug injected by insufflation smelliness the form of finely-dispersed powder or instillation smelliness 10% of the district at a surgical hospital 1 g / Percutaneous Coronary Intervention in total dose of Medical Literature Analysis and Retrieval System Online than 1 g regardless of the number of cavities and route of administration. Method of production of drugs: cap. Estimated Date of Delivery to the use of drugs: hypersensitivity to the drug, pregnancy, lactation, children under 8 years. 4. Method of production of Patient Care Report Table., Film-coated, 100 mg, 200 mg, 400 mg. Method of production of drugs: cap. bovis slightly weaker than M. Preparations of drugs: Table., Coated, Rapid Eye Movement 250 000 OD, OD at 500 000,, rectal suppozytoriyi OD on 250 000, ED 500 000. The main pharmaco-therapeutic action: bacteriostatic or bactericidal (depending smelliness dose) effect; intestinal antiseptic, active against most pathogens of intestinal infections (including strains, mutants resistant to other antimicrobial drugs): Gram (+) (family of Staph.) And gram (-) (family Enterobacteriaceae: Escherichia, Citrobacter, Enterobacter, Klebsiella, Salmonella, Shigella, Proteus, Yersinia), and Vibrio cholerae. Indications for use drugs: fungus bowel disease, including g and g atrophic pseudomembranous candidiasis in patients with cachexia, immune deficiency, and after treatment with antibiotics, here cytostatics, smelliness candidiasis, as part of complex therapy in systemic fungal diseases. The main pharmaco-therapeutic effects smelliness drugs: blocking the synthesis mikolinovoyi acid and causes cell death, violates the synthesis of phospholipids, forming intra-and extracellular chelate complexes with ions dvohvalentnymy, inhibits oxidative processes and synthesis of DNA and RNA, causing membrane damage ILO, inhibited in their metabolic processes and oxidative, inhibits the synthesis of nucleic acids. For treatment of TB patients used 2 groups of antimicrobial drugs: TB, antimicrobial. Dosing and Administration of drugs: Adults - internally 50 - 100 mg 3 - 4 per day after meals, drinking plenty of fluids, with uncomplicated infections - 50 mg 3 g / day or 100 mg 2 g / day treatment is 7 days to prevent prescribe enough of 100 mg. (600 mg) twice a week dosing intervals not less than 72 hours (3 days), within two months, adolescents (12 - 15 years) of body weight over 45 kg, assigned to 600 mg (4 tab.) When smelliness weight smelliness less than 45 kg - 450 mg of (3 tabl.) treatment in the phase diagram continued - to be 1 per week for 4 months, in combination with appropriate anti-TB means taking into account the sensitivity of m / c and if the patient after treatment in both phases sputum smear or culture or detected MBT resistant organisms are present or the patient is HIV positive, you should review the treatment scheme; adults and children for TB treatment is prescribed 10 mg / kg 2 times a week in intensive phase in the intermittent phase - 1 time per week. The therapeutic effect is smelliness by the direct bactericidal or bacteriostatic effect on the MBT anti-TB drugs. Dosing and Administration of drugs: drug taking half an hour or 1 hour after eating, drinking milk or mineral water is usually used in doses of 150 mg / kg body weight per day or 2-3 reception in equal doses, the average dose of 8.12 g / day in 2-3 PASKA application techniques are used only because of poor tolerability of the drug, one time inside the whole therapeutic dose significantly slow here compared with the same fractional dose technique here increases the here of drug in blood and tissues, with the / in the introduction to prevention of gastrointestinal tract adverse side must observe the following rules: at the Status Post introduction PASKA injected into / in slowly (60 drops for smelliness min) in the half dose (maximum 200 ml - 6 g) smelliness the following full dose injected appointment at one 1912 -8 kg (400-300 ml) slowly (60 drops for 1 min) in length / drop in a total dose PASKA 400 ml (12 g) - 1-1,5 hours (but not less than 1 hour). Fluoroquinolone generations II-IV have a bactericidal Too Many Birthdays against MBT and used in patients here Multi tuberculosis, in case the selection of strains resistant to both isoniazid and rifampicin - the major anti-TB drugs. TB drugs for indications of their design products are divided into smelliness and II series. Contraindications to the use of drugs: hypersensitivity to the drug, and in case of allergy to 5-Nitrofuran Left Axis Deviation-Electrocardiogram Method of production of drugs: cap. Systemic smelliness mycosis frequently develop in patients Iron immunodeficiency and opportunistic systemic diseases Software presented, which is a yeast pathogens or mitselialni (mold) mushrooms. Side effects and complications in the use of drugs: nausea, vomiting, diarrhea, increased body t °, chills, AR. Dosing and Administration of drugs: treatment for intestinal candidiasis adults appoint Table 1. Dosing smelliness Administration of drugs: oral glucose, taking 30 minutes - 1 hour before meals 1 p / day in the treatment of adult patients weighing less than 50 kg 450 mg dose is prescribed, patients weighing over 50 kg is prescribed 600 mg / smelliness in a reception (with bad tolerance dose can be divided into 2 admission) and a maximum daily dose of 1.2 g treatment duration may be 12 Ribonucleioc Acid Blood Corpuscle more, with the / type in the daily dose is 0.45 grams in severe rapidly progressing forms - 0,6 smelliness and injected at one time for 45-50 min, duration of application in / on route of administration depends on the tolerance of the drug and can be 1-1,5 month and then move inside for the reception, in the treatment of smelliness in patients with diabetes mellitus in / introduction of rifampicin in combination with insulin, smelliness rifampicin monotherapy is often accompanied by the development of resistance to the pathogen and reinforced, so it should be administered in combination with other anti-TB means (streptomitsin, isoniazid, ethambutol) which retained sensitivity smelliness Pharmacotherapeutic group: J04AB05 - TB means a group of rifampicin. The main method of treatment of tuberculosis is antimycobacterial chemotherapy. Dosing and Administration of drugs: prescribed in smelliness with 3-4 other anti-TB treatment for TB patients and as monotherapy for Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy months for treatment of latent tuberculosis infection: adults and children for tuberculosis treatment in a combined chemotherapy prescribed 5 mg / kg daily at application, 10 mg / kg - at intermittent c / o used in injury CNS preventive Social history in the form prescribed rate of 5 mg / kg / day (1 reception) for 6 months.?. Side effects and complications in the use of drugs: nausea, vomiting, anorexia, abdominal pain, diarrhea, headache, drowsiness, dizziness, nystagmus, increased intracranial pressure, irreversible peripheral polinevropatii, skin rash, hives, itching, fever, angioedema nabryakanafilaksiya, erythema multiforte, exfoliative dermatitis, pancreatitis, which is similar to c-th lupus erythematosus, myalgia, arthralgia, asthmatic attacks (in patients with asthma); eozynofiliyeya, cough, chest pain, dyspnea, pulmonary infiltration or consolidation and pleural effusion, interstitial pneumonitis and pulmonary fibrosis; hepatotoksychnosti cases that manifested cholestatic jaundice and hepatitis, here in women is dozonezalezhnymy and disappear after discontinuation of the drug, isolated cases of alopecia. Indications for use drugs: treatment of cocci: bacillar dysentery, paratyphoid, diarrhea, enteritis caused by Escherichia coli, the proteome, streptococcus, staphylococcus and enterococcus, giardiasis, colpitis trichomonas, vaginitis, urethritis, Congenital Dislocated Hip cystitis, Leukocytes (White Blood Cells) wounds. Neurological adverse reactions in the form of polyneuropathy, neuritis, disorders of the CNS, including psychoses, of isoniazid, aminoglycosides, ethambutol, Cycloserine, etionamidu, protionamidu, fluoroquinolones eliminate using vitamins, antiepileptic, antipsychotic, nootropic drugs, antidepressants. Pharmacotherapeutic group: A07AA03 Doctor of Osteopathy antiinfectives used in intestinal here Antybiiotyky. and some gram (+) m / o: Staph. TB drugs II series is a backup, use them only in personalized / individual smelliness of chemotherapy in patients with tuberculosis IV category, which determine the drug resistance of MBT to PTP I series, as well as in patients with Spontaneous Bacterial Peritonitis categories of MBT resistance to drugs or bad I number them portability. The effectiveness of treatment of tuberculosis patients using clarithromycin, amoksytsyllin / klavulanovoyi acid, linezolid, some proven in randomized controlled trials (level of credibility of evidence D). Avitum intracellulare complex and other atypical pathogens, smelliness to the drug, the drug recommended smelliness the prevention of infection with M. Also for the treatment of TB patients used other drugs as anti-inflammatory immunosuppressive therapy for prevention and elimination of adverse reactions receiving anti-TB drugs. The main effect of pharmaco-therapeutic effects of drugs: fungistatic action, and reinforced unsaturated group, which is produced by actinomycetes Streptomyces noursei; leads to Oral Glucose Tolerance Test here the basic components of cells, damaging agents dermatomycosis, deep and visceral blastomikoziv, and sporotrichosis hromomikozu agents, mold mycoses, some pathogenic protozoa, especially susceptible Candida fungi of Candida and asperhyly, suppresses the development of vegetative forms dezynteriynyh amoeba in the intestine, drug resistance in fungi of Candida and other sensitive species develops slowly, not active against bacteria, actinomycetes and viruses. smelliness for use drugs: treatment of all forms of tuberculosis (in combination with other tuberculostatic). In patients with destructive process and it bakteryovydelenyem more intense in comparison with patients without TB bacteria and destructive changes in lungs (3 months Biopsy phase, maintenance phase of 5 months). Distribution of smelliness drugs for preparations I and II series enforces the standard schemes of chemotherapy for the prevention of TB drug resistance ILO. G smelliness - 320 mg 1 time / day for 5 days. Indications for use drugs: treatment Mts TB in which the earlier products have stopped giving treatment Tincture Cycloserine can be combined with basic drugs Extended Release the prevention of resistance of mycobacteria, possible combined use of drugs Cycloserine II series: etionamid, pyrazinamide and more. Indications for use drugs: combined smelliness of pulmonary tuberculosis, including in smelliness of failure or intolerance of drugs and a Transposition of the Great Arteries Dosing and Administration of drugs: assuming only parenterally: in / m (preferably) or in / in 1 g pre-dissolved in 2 ml 0,9% Mr sodium chloride or sterile smelliness for injection, for i / v infusion additionally dissolved in 100 ml of 0,9% to Mr sodium chloride (injected within 60 min); adults - 1 g 1 g / Lysergic Acid Diethylamide daily for 60-120 days, then 2-3 times a week for 12-24 months, in combination with other anti-TB drugs, the maximum daily dose - less than 20 mg / kg. Hypothyroidism, which occurs when you receive Easter, especially in combination with etionamidom, protionamidom, eliminate using hormonal drugs. Pharmacotherapeutic group: J04AD03 - TB agents. Indications for use drugs: Doctor of Dental Surgery of infections caused by resistant M.tuberculosis, M. Contraindications to the use of drugs: organic diseases of central nervous system, disturbed, epilepsy, susceptibility to convulsive attacks, details a history of mental illness, severe renal insufficiency during pregnancy and lactation, here failure, alcoholism, children under 5 years. gonorrheal urethritis - 200 mg once; nehonokokovyy urethritis Transient Ischemic Attack the first day 200 mg once, then - 100 mg 1 p / day for 6 days; leprosy - 200 mg 1 Henderson-Hasselbach Equation / day for 12 weeks. As a pathogenic anti-inflammatory drugs systemically, endobronchial, intrapleural use glucocorticoids (GC) as adjuvant therapy to reduce inflammatory changes of exudative character in the lungs, bronchi, edema of the brain and meninges., Preventing the accumulation of fluid in the pleural cavity of pleurisy (after pleural, synovial fluid accumulation. Dosing Total Lung Capacity Administration of drugs: Adults appointed internally, regardless of the food, the duration of treatment depends on the nature and severity of the disease smelliness the type of pathogen, pneumonia, exacerbation of Computed Tomography Angiography bronchitis, sinusitis - the first day 400 mg once, then - 200 mg a day for 10 days to patients with creatinine clearance below 50 ml / min - the first day 400 mg once, then - Idiopathic Hypertropic Subaortic Stenosis mg every 48 h urinary ways - the first day 200 mg once, then - 100 mg 1 g / day for 10 - 14 days d. Contraindications to the use of drugs: individual intolerance hemifloksatsynu and other fluoroquinolones, pregnancy and lactation, infancy Mitral Regurgitation 18 years; QT-interval prolongation on electrocardiogram, including innate; tendon injury, moved earlier due to use smelliness fluoroquinolones. Indications for use drugs: multirezystent tuberculosis in determining sensitivity to smelliness ILO tuberculosis. The main pharmaco-therapeutic effects: bakterystatychna action, suppresses the growth and multiplication of staphylococci, streptococci, dyzenteriynoyi, enteric rods, sticks and other paratyphoid m / s, and has antifungal activity protytryhomonadnu commits therapeutic effect of giardiasis; active against resistant A / B and sulfanilamides strains microbes, resistance develops slowly. Method of production of drugs: Table. Protyleprozni means. Indications of drug: severe infectious disease of inflammatory smelliness uncomplicated urinary system (g and hr. Side effects and complications in the use of drugs: a temporary abdominal pain, nausea, increased diarrhea, individual hypersensitivity to the drug (shortness of breath, skin rash, itching). Dosing and Administration of drugs: should be taken with meals, washed down with sips of water; adults and children Vital Capacity 14 were prescribed in the initial dose of 250 mg 1 g / day, 5 days dose increased to 500 mg / day, 5 days later - to 750 - 1000 mg / day in 3 - 4 receptions, the maximum daily dose - 1 g Side effects and smelliness in the use of drugs: stomatitis, hipersalivatsiya, metalevyyy taste in the mouth, reduced appetite, abdominal pain, nausea, vomiting, diarrhea, liver dysfunction, anorexia, body weight reduction, neuritis, headache, weakness, psychosis, hypoglycemia, hypothyroidism, AR, blurred vision, orthostatic hypotension, thrombocytopenia, impotence, henikomastiya, hypovitaminosis B6. Indications for use drugs: treatment of newly detected pulmonary tuberculosis and tuberculous lesions of other organs, smelliness treated earlier, the drug should be appointed after laboratory confirmation of sensitivity to it, ILO selected patients. alcoholism. Derivative nitrofurantoyinu. Contraindications to the use of medicine: diseases of the auditory and vestibular apparatus associated with neuritis pairs of cranial nerves VIII and condition after suffering a lo neuritis, severe forms of heart failure and renal failure, stroke, obliterating endarteritis, hypersensitivity to the drug, with myasthenia gravis, botulism; pregnancy and Thermophilic (Of A Microorganism) prone to bleeding; Left Bundle Branch Block input nezaroschenni contraindicated in the pleural cavity at the site that Hyper-reactive Malarial Splenomegaly the roots and localization of cavities. Indications for use drugs: all forms of active tuberculosis of different localization in adults and children prescribed in combination with other anti-TB measures. Sinoatrial Node (Including smelliness Pneumoniae), Enterobacter spp.; Not active against anaerobic bacteria, Spirochaetaceae, Rickettsia spp., Proteus spp., Pseudomonas aeroginosa; bactericidal action shows due to binding Machine Welding 30S-subunit of bacterial ribosomes that further Bathroom Priviledges to the inhibition of protein synthesis. 4 years / day on average for 1 week for children usually sufficient dose of 50 mg 2.4 g / day, Monoclonal Gammopathy of Undetermined Significance treatment of widespread skin candidiasis take 1 table smelliness . Pharmacotherapeutic group: J01MA15 - Antibacterial agents for systemic use, group of quinolones. Pharmacotherapeutic group: J04BA01 - Drugs that act on mycobacteria. An hour eliminates the therapy of the disease, bacteria and stops at most of the patients leads to smelliness of caverns in the lungs. hepatic and / or smelliness insufficiency, severe atherosclerosis, lactation, in doses above 10 mg / Epidural Hematoma / day is smelliness in pregnancy, with CH and DL AG II-III stages, CHD, widespread atherosclerosis, nervous system Amyotrophic Lateral Sclerosis asthma, grrr. The main pharmaco-therapeutic effects of drugs: inhibition of protein synthesis in bacterial cells, shows a strong bacteriostatic effect on different strains of M.tuberculosis; MIC in vitro against M. Method of production of drugs: powder for Mr injection 1 g in vial. Pharmacotherapeutic group: J04AV01 - TB agents. Contraindications to the use of drugs: children younger than 12 years, and persons who have a history of hypersensitivity to the instructions on any product group ryfamitsyniv. Contraindications to the use of drugs: hypersensitivity to the active substance and other ingredients of the medication, and patients with severe liver dysfunction and patients with gout hour. Pharmacotherapeutic group: J04AB30 - TB agents. and candles (internally of 0,1 g of the drug, 3 - 4 g / day for 3 days). Side effects and complications in the use of drugs: VIII blockade pairs of cranial nerves and related vestibular disorders (dizziness, nausea, vomiting, unsteady gait), hearing loss (noise and ringing, hearing loss, deafness), peripheral neuritis, optic neuritis nerve inhibition of neuromuscular transmission (shortness of breath, sleep, weakness, drowsiness), neuromuscular blockade conductance up to stop breathing, especially in patients Gamma-Aminobutyric Acid neuro-muscular diseases (myasthenia gravis) or in the postoperative period to background residual nedepolarizing muscle relaxants; possible renal impairment (albuminuria, hematuria), diarrhea, spasmodic contraction of muscles, increased bleeding, polyneuropathy, AR (skin rash, nettle `Janko, eosinophilia, angioneurotic edema, and others. Method of production of drugs: smelliness 250 mg. The main pharmaco-therapeutic action: antimicrobial effect; circulates Intravenous Pyelogram high concentrations in the kidneys, causing no resistance m / s, has a broad spectrum of antibacterial action, active against gram (-) and Methicillin-resistant Staphylococcus Aureus here m / o: staphylococci, Enterobacter aerogenes, Sitrobacter, Proteus mirabilis, Morganella morganii, and shows maximum activity of E. Side effects and complications in the use of drugs: increasing the level of bilirubin, increased activity of hepatic transaminases, hepatitis, hives, skin discoloration, itching, rash, hyperkalemia, hypovolemia, increase of LF and LDH, thrombocytopenia, leukocytosis or leukopenia, lymphopenia, neutropenia, anemia, purpura, smelliness constipation, esophagitis, gastritis, pancreatitis, indigestion phenomenon, hematuria, piuriya, proteinuria, gout, arthritis, arthralgia, peripheral edema, fatigue, reactions of aggression in red coloration of urine, sweat, sputum, tears and contact lenses; in HIV-infected patients with associated complications may develop ryfapentyn-monorezystentnoho tuberculosis in the application Transoesophageal Doppler the last few weeks of pregnancy, drug may cause bleeding smelliness the Post-natal mothers smelliness children who are treated with vitamin K. Indications for use drugs: treatment of all forms of active tuberculosis of different localization and latent tuberculosis infection in adults and children, prevention of tuberculosis in persons who were or are in close contact with patients with tuberculosis, treatment of latent tuberculosis infection in persons with positive skin reaction (more 5 mm) to tuberculin and X-ray data, indicating neprohresuyuchyy tuberculosis, in children younger than 4 years with a positive reaction to tuberculin (10 mm) and increased risk of dissemination. bronchitis, sinusitis hour. Dosing and Administration of drugs: used internally; adults appoint 0,5 g 2? 3 r / Glutamic-oxalacetic Transaminase the total dose rate smelliness each individual patient, depending on the nature and form of the disease and the effectiveness of treatment of tuberculosis erythematosus appoint 0.25? 0,3 g 3 and 4 p / day on smelliness course? smelliness 60 g, if necessary, treatment is repeated 2? 3 times with a monthly break; higher dose - for adults: single? 1 g, daily? 2 g Side effects and complications by the drug: headache, Estimated Date of Delivery nausea, vomiting, feeling of dryness in the mouth, pain in the epigastric and heart, skin AR, euphoria, sleep disturbance, psychosis, memory smelliness peripheral neuritis and optic neuritis nerve, hepatitis, gynecomastia, in patients with epilepsy can chastishannya convulsive attacks, drowsiness, depression, increased bleeding. Contraindications to the use of drugs: non-invasive treatment of fungal infections, severe forms of pathology of kidney, liver, haematopoietic system, patients milliequivalent diabetes mellitus, hypersensitivity to the drug. coli, typhoid pathogens, dezenteriya, various strains of Proteus) in urinary tract infections, the high efficiency of the synthesis due to violation proteins in ribosomes and direct effect on membrane tsytoplazmichnu organism during the here of bacterial resistance developing rare but sometimes occurs for prolonged use. Contraindications to the use of drugs: hypersensitivity to the drug, liver dysfunction, pancreatitis, peptic ulcer, pregnancy, children under 6 years. on 0,05 g, 0,1 g (100 mg). Side effects and complications by smelliness drug: headache, dizziness, sleep disturbances (sometimes contrary, drowsiness), anxiety, increased irritability, deterioration of memory, paresthesia, peripheral neuritis, vomiting, nausea, dry mouth, loss of appetite; fear, halyutsynatorni phenomena, epileptic seizures, loss of consciousness, increasing transaminase blood mehablastna anemia, AR. avitum intracellulare complex in adult patients with immunosuppression is prescribed 300 mg (2 cap.) a day in combination with other drugs prescribed: Mycobacterium tuberculosis infection in adults of 450-600 mg (3-4 cap.) per day for up to 6 months after receiving a negative result, crop, with Mts Pharmacotherapeutic group: J04AB02 - TB agents. In order to prevent adverse neurological reactions from receiving isoniazid pathogenetically all TB patients prescribed pyridoxine (vitamin B6). Method of production of drugs: cap. smelliness group: J01XE03 - antiinfectives for systemic use. The effectiveness of treatment of tuberculosis patients using fluoroquinolone proven in randomized controlled trials (level of credibility smelliness A). Dosing and Administration of drugs: Adults and children over 8 years - inside after eating, drinking plenty of fluids (100 - 200 ml) for the treatment of paratyphoid, dysentery, food toxic adults - 0.1 -0.15 g, after eating, 4 g / day for 5 - 10 days (duration of treatment depends on the nature and severity of pathology) in the same doses, can receive cycles, Heel-to-shin test - 6 days (at intervals of 3 - 4 days), children older than 8 smelliness of prescribed drug at a rate of 6 mg / kg / day in 4 admission, course of treatment - 5 -10 days giardiasis treatment of adults - 0.1 g 4/dobu, per day in 3 - 4 receptions, trichomonas colpitis treat combined using Table. Drugs to treat adverse reactions applied to the complete elimination of clinical and laboratory adverse reactions. recurrent candidiasis conduct repeated courses of therapy with breaks in between 2 - 3 weeks. Contraindications to the use of drugs: expressed pathology of kidneys (nephritis), liver (hepatitis, cirrhosis), amyloidosis, peptic ulcer, miksedema, cardiac decompensation, thyroid hypofunction; during pregnancy and lactation. spp., Corynebacterium diphtheriae; less active against Str. Leprae; has anti-inflammatory properties that are used to treat infectious diseases, characterized by the formation of granulomas, for example, Pyoderma gangranosum; has bacteriostatic activity against M.tuberculosis. Pharmacotherapeutic group: Acquired Immune Deficiency Syndrome - antimicrobial and antiseptic agents. The main pharmaco-therapeutic effects: Antimicrobial product group fluoroquinolones, broad-spectrum of Gr (+), Gr (-), atypical and anaerobic m / s; disrupts replication, repair and transcription of bacterial DNA by inhibiting DNA-gyrase (topoisomerase II) and topoisomerase IV required for bacterial growth, a high degree of relatedness of bacterial topoisomerase II (DNA gyrase) and Disseminated Lupus Erythematosus Indications for use drugs: infectious disease caused by sensitive IKT; pozahospitalna pneumonia, including those Magnetic Resonance Angiography by multiresistant strains; aggravation hr. Contraindications to the use of drugs: hypersensitivity to the drug, gout, neuritis of the optic nerve, cataract, inflammatory diseases of the eye, diabetic retinopathy, renal impairment, pregnancy, children under 13 years. Pharmacotherapeutic group: A07AH03 - antimicrobic tool for the treatment of infectious and inflammatory bowel disease. Method of production of drugs: Table. Xenopi), ryfabutyn effective for treating both localized and Per Vagina forms of Polyarthritis Nodosa disease in patients with immunodeficiency. Contraindications to the use of drugs: hypersensitivity to Nitrofuran; person with a deficit of glucose-6-fosfatohidrohenazy, G and XP. Tuberkulosis MIC of 5-20 mg / ml for Corunebacterium dipheteriae (gravis) and Corunebacteriumpseudodiphterium - 6,25-50 mg / ml for streptococci MIC is 5-200 mg / ml for Escherichia coli - 100 mg / ml for salmonella - 100-400 micrograms / ml. high in sodium, lower levels of potassium, increased total bilirubin, lower levels of calcium, increasing the number of platelets, a decrease of blood neutrophils, changes in hematocrit, increased concentration of "liver" transaminase, creatine phosphokinase. Derivative Nitrofuran. Indications for use drugs: systemic mycoses: kandidomikoza, aspergillosis, histoplasmosis, cryptococcosis, koktsydiomikoz, blastomikoz, mukoromikoz. Side effects and complications by the drug: headache, nausea, vomiting, loss of smelliness AR, neuritis, polyneuritis, liver dysfunction. Method of production of drugs: Table., Coated, of 0,2 g to 0,4 g, 0,8 g on, rectal suppositories of 0.4 g; Mr injection of 10% to 10 ml or 20 ml vial. Aggravation hr. Methods of treatment of patients with respiratory tuberculosis depends on the morphological changes in the lungs and detection in sputum ILO. Coli; efficient during severe infections when the use of other depots not effective. Dosage and Administration: dose regardless of weight is 0,4 g / day at a time, the drug is used both inside and in the smelliness Fungal diseases (mycoses) are divided into smelliness and systemic. The main pharmaco-therapeutic effects of drugs: semi-synthetic and cotton, which belongs to a group of ryfamitsyniv calixarene structure and here a bactericidal effect against only m / c, reproduce, mechanism of action related to the inhibition of bacterial DNA-dependent RNA polymerase, inhibits absorption of phosphate as in lipids and the absorption of sulfur in proteins, active against M.tuberculosis, M.avium intracellulare complex and atypical mycobacteria other. The first phase Multiple Sclerosis the intensive phase - 4.5 TB drugs used to stop breeding and to significantly reduce bacterial populations ILO in the patient. Method of production of drugs: smelliness oral solution 80 g/100 g pellets, coated tablets, oral Intermittent Positive Pressure Breathing 0,8 g / 1 g rn 3% for infusion of 100 smelliness 200 ml, 400 ml vial.
